Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin consolidation in stage I/II classical Hodgkin lymphoma with PET positivity after 2 cycles of ABVD
2013-000734-35Phase 2Completed
- Sponsor
- LYSARC
- Start
- Jul 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by LYSARC. Primary endpoint: Progression-free survival at 2 years. Started Jul 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2013-000734-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000734-35.